secwatch.observer — SEC 8-K summary
======================================

Issuer:     Rezolute, Inc. (RZLT)
CIK:        0001509261
Form:       8-K
Filed at:   2023-06-20T23:59:59+00:00
Accession:  0001104659-23-072543
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 7.01
LLM model:  deepseek-v4-flash:cloud@v2

Rezolute reports first use of RZ358 for insulinoma; patient achieved substantial hypoglycemia benefit
--------------------------------------------------------------------------------

- Patient with metastatic insulinoma and intractable hypoglycemia received RZ358 under compassionate use IND.
- Treatment began Q4 2022; patient continues therapy with substantial benefit and improved quality of life per Dr. Patti.
- Case presented as late-breaking abstract at ENDO 2023 on June 16, 2023; abstract published in Journal of Endocrine Society.
- This marks the first time Rezolute's RZ358 has been used for insulinoma indication.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1509261/000110465923072543/0001104659-23-072543-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1509261/000110465923072543/tm2319018d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-072543

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer